🧪 Lupin Strengthens Growth with US Market Gains & New Launches

Lupin is witnessing improved performance driven by strong traction in the US market and new product launches. The company is benefiting from growth in generics, specialty drugs, and respiratory portfolio, while cost optimisation efforts are supporting margins. Regulatory approvals and pipeline expansion are adding to future visibility. Management remains optimistic, backed by product pipeline strength, global expansion, and improving operational efficiency. 📌 StockYard Take: US recovery and pipeline strength position Lupin for steady growth in the pharma space. #Lupin #PharmaStocks #USMarket #Generics #StockYardResearch